Market Cap | 181.05M | P/E | - | EPS this Y | 2.60% | Ern Qtrly Grth | - |
Income | -166.43M | Forward P/E | -1.97 | EPS next Y | 50.40% | 50D Avg Chg | -20.00% |
Sales | 162.47M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -52.00% |
Dividend | N/A | Price/Book | 13.28 | EPS next 5Y | - | 52W High Chg | -79.00% |
Recommedations | 2.50 | Quick Ratio | 1.88 | Shares Outstanding | 48.12M | 52W Low Chg | 9.00% |
Insider Own | 3.17% | ROA | -30.87% | Shares Float | 39.41M | Beta | 1.24 |
Inst Own | 106.45% | ROE | -1,028.56% | Shares Shorted/Prior | 6.04M/5.35M | Price | 3.83 |
Gross Margin | 35.72% | Profit Margin | -102.44% | Avg. Volume | 1,492,277 | Target Price | 1.67 |
Oper. Margin | -75.83% | Earnings Date | Feb 26 | Volume | 1,114,010 | Change | -11.25% |
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter Pro and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips and reagent plates to setup and process samples in instruments; and Prosigna in vitro diagnostic kits. The company is also developing GeoMx DSP system to enable the field of spatial biology. It has collaboration with Lam Research Corporation for the development of NGS sequencing platform and related assays; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer, as well as collaboration with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
GRAY R BRADLEY | President and CEO President and CEO | May 25 | Buy | 5.80 | 30,000 | 174,000 | 338,395 | 05/30/23 |
Bailey K Thomas | Chief Financial Offi.. Chief Financial Officer | May 26 | Buy | 5.763 | 15,000 | 86,445 | 75,388 | 05/30/23 |
Norden Gregory | Director Director | Apr 27 | Option | 8.45 | 8,768 | 74,090 | 32,568 | 04/28/23 |
FINNEY ELISHA W | Director Director | Jun 17 | Sell | 12.41 | 1,945 | 24,137 | 6,595 | 06/21/22 |
Bailey K Thomas | Chief Financial Offi.. Chief Financial Officer | Mar 10 | Sell | 33.81 | 5,000 | 169,050 | 16,105 | 03/11/22 |
GRAY R BRADLEY | President and CEO President and CEO | Mar 06 | Option | 0 | 24,526 | 198,596 | 03/09/22 | |
GRAY R BRADLEY | President and CEO President and CEO | Mar 06 | Sell | 33.06 | 9,667 | 319,591 | 188,929 | 03/09/22 |
BEECHEM JOSEPH M | SVP, Research & Deve.. SVP, Research & Development | Mar 06 | Option | 0 | 6,505 | 85,399 | 03/09/22 | |
BEECHEM JOSEPH M | SVP, Research & Deve.. SVP, Research & Development | Mar 06 | Sell | 33.06 | 2,968 | 98,122 | 82,431 | 03/09/22 |
Bailey K Thomas | Chief Financial Offi.. Chief Financial Officer | Mar 06 | Option | 0 | 7,753 | 24,163 | 03/09/22 | |
Bailey K Thomas | Chief Financial Offi.. Chief Financial Officer | Mar 06 | Sell | 33.06 | 3,058 | 101,097 | 21,105 | 03/09/22 |
GRAY R BRADLEY | President and CEO President and CEO | Sep 10 | Sell | 58.15 | 33,334 | 1,938,372 | 135,824 | 09/10/21 |
GRAY R BRADLEY | President and CEO President and CEO | Sep 10 | Option | 6.72 | 12,500 | 84,000 | 169,158 | 09/10/21 |
GRAY R BRADLEY | President and CEO President and CEO | Apr 13 | Sell | 66.14 | 26,863 | 1,776,719 | 169,803 | 04/13/21 |
GRAY R BRADLEY | President and CEO President and CEO | Apr 13 | Sell | 66.32 | 8,817 | 584,743 | 196,666 | 04/13/21 |
GRAY R BRADLEY | President and CEO President and CEO | Apr 13 | Option | 4.32 | 25,000 | 108,000 | 162,507 | 04/13/21 |
GRAY R BRADLEY | President and CEO President and CEO | Apr 13 | Sell | 62.52 | 33,333 | 2,083,979 | 129,174 | 04/13/21 |
BROWN J. CHAD | SVP, Sales & Marketi.. SVP, Sales & Marketing | Apr 13 | Sell | 68.78 | 4,948 | 340,323 | 04/13/21 | |
BROWN J. CHAD | SVP, Sales & Marketi.. SVP, Sales & Marketing | Apr 13 | Sell | 66.32 | 1,335 | 88,537 | 9,702 | 04/13/21 |
BEECHEM JOSEPH M | SVP, Research & Deve.. SVP, Research & Development | Apr 13 | Sell | 66.14 | 10,035 | 663,715 | 80,035 | 04/13/21 |
BEECHEM JOSEPH M | SVP, Research & Deve.. SVP, Research & Development | Apr 13 | Sell | 66.32 | 1,778 | 117,917 | 90,070 | 04/13/21 |
Bailey K Thomas | Chief Financial Offi.. Chief Financial Officer | Apr 13 | Sell | 66.32 | 1,335 | 88,537 | 19,316 | 04/13/21 |
HERSHBERG ROBERT | Director Director | Feb 18 | Option | 11.2 | 1,188 | 13,306 | 3,078 | 02/18/21 |
HERSHBERG ROBERT | Director Director | Feb 18 | Sell | 81.17 | 1,188 | 96,430 | 1,890 | 02/18/21 |
Malloy Kirk | Director Director | Jan 13 | Option | 11.92 | 2,500 | 29,800 | 3,490 | 01/13/21 |
Malloy Kirk | Director Director | Jan 13 | Sell | 66.53 | 2,500 | 166,325 | 990 | 01/13/21 |